Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Cancer entities : Sorrento therapeutics, inc. save search
Caris Life Sciences, Prostate Cancer Clinical Trial Consortium and Sorrento Therapeutics Announce Collaboration to Advance Precision Medicine Development Using Comprehensive Genomic Profiling
Published: 2022-06-02 (Crawled : 11:00) - prnewswire.com
SRNE | $0.015 -25.0% -8.85% 140K
|
Health Technology
|
| O: -5.64%
H: 0.0%
C: 0.0%
collaboration genomic trial therapeutics cancer prostate cancer
Sorrento Announces FDA Authorization to Proceed With Phase 2 Study of Abivertinib (Fujovee™) to Treat Metastatic Castrate Resistant Prostate Cancer (MAVERICK Trial)
Published: 2022-05-17 (Crawled : 17:00) - biospace.com/
SRNE | $0.015 -25.0% -8.85% 140K
|
Health Technology
|
| O: 4.17%
H: 6.0%
C: 4.67%
fda authorization cancer phase 2 prostate cancer
Sorrento’s License Partner, Lee’s Pharm, Announces Full Enrollment of 498 Patients in a Phase III Trial of Socazolimab (Anti-PD-L1 Antibody) for First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer (ES-SCLC)
Published: 2022-05-17 (Crawled : 15:20) - globenewswire.com
SRNE | $0.015 -25.0% -8.85% 140K
|
Health Technology
|
| O: 4.17%
H: 6.0%
C: 4.67%
treatment license trial cancer enroll antibody
Levena Biopharma, A Sorrento Company, Announces Positive Clinical Data for Its Out-Licensed A166 Product Candidate, A Third-Generation Anti-HER2-ADC, In Treating Heavily Pretreated HER2-Positive Breast Cancer Patients
Published: 2022-05-03 (Crawled : 13:20) - globenewswire.com
SRNE | $0.015 -25.0% -8.85% 140K
|
Health Technology
|
| O: 1.85%
H: 6.06%
C: 3.03%
positive cancer license breast cancer her2- her2
The Worldwide Cancer Pain Industry is Expected to Reach $9.9 Billion by 2030
Published: 2022-03-09 (Crawled : 17:00) - prnewswire.com
TEVA | $12.88 0.16% -0.08% 7.9M
|
Health Technology
|
| O: 2.57%
H: 4.49%
C: 3.17%
SRNE | $0.015 -25.0% -8.85% 140K
|
Health Technology
|
| O: 2.4%
H: 10.33%
C: 8.45%
cancer
Sorrento Completes Acquisition of Virex Health, Will Commercialize Next-Generation at-Home Diagnostic Testing That Rivals PCR-Level Sensitivity for Daily Covid-19 Tests and Early Cancer Diagnosis
Published: 2022-02-01 (Crawled : 14:30) - globenewswire.com
SRNE | $0.015 -25.0% -8.85% 140K
|
Health Technology
|
| O: 1.74%
H: 0.85%
C: -1.42%
diagnostic covid-19 health als acquisition covid test cancer
Sorrento Publishes an Abivertinib Teaser Entitled “Abivertinib – A Franchise Oral Therapeutic for Cancer, COVID-19 and Autoimmune Diseases”
Published: 2021-11-29 (Crawled : 16:00) - biospace.com/
SRNE | $0.015 -25.0% -8.85% 140K
|
Health Technology
|
| O: 3.87%
H: 0.0%
C: 0.0%
covid disease cancer
Sorrento Announces Publication of Significant Positive Pivotal Trial Results of Abivertinib for the Treatment of Non-Small Cell Lung Cancer (NSCLC) in the Peer-Reviewed Journal Clinical Cancer Research
Published: 2021-11-12 (Crawled : 15:00) - globenewswire.com
SRNE | $0.015 -25.0% -8.85% 140K
|
Health Technology
|
| O: 1.34%
H: 0.0%
C: 0.0%
treatment lung cancer positive results cancer research trial trial results
Sorrento’s License Partner, Lee’s Pharmaceutical Announces NDA Filing Acceptance by NMPA for Anti-PD-L1 Antibody Socazolimab for Treatment of Recurrent or Metastatic Cervical Cancer
Published: 2021-11-01 (Crawled : 14:00) - biospace.com/
SRNE | $0.015 -25.0% -8.85% 140K
|
Health Technology
|
| O: -0.15%
H: 5.26%
C: 2.92%
treatment cancer antibody license
FDA Authorizes Sorrento Phase 2 Trial of Epidural Resiniferatoxin for the Orphan Indication of Control of Intractable Cancer Pain
Published: 2021-10-13 (Crawled : 13:15) - globenewswire.com
SRNE | $0.015 -25.0% -8.85% 140K
|
Health Technology
|
| O: 2.45%
H: 0.52%
C: -0.15%
fda phase 2 cancer trial authorized
Increasing Adoption of Targeted Cancer Therapies to Propel Oncolytic Virus Immunotherapy Market, Says TMR
Published: 2021-08-03 (Crawled : 13:15) - prnewswire.com
SRNE | $0.015 -25.0% -8.85% 140K
|
Health Technology
|
| O: -0.48%
H: 0.72%
C: -1.33%
REPL | $6.42 -0.47% -0.31% 550K
|
Health Technology
|
| O: 0.84%
H: 3.45%
C: 1.78%
ONCR | $0.126 -75.95% 140K
|
Health Technology
|
| O: -0.24%
H: 1.98%
C: -1.74%
immunotherapy therapy cancer
Lee’s Pharmaceutical Announces First Patient Dosed With its Anti-PD-L1 Antibody Socazolimab, Licensed From Sorrento Therapeutics, as a First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer
Published: 2021-07-23 (Crawled : 16:00) - globenewswire.com
SRNE | $0.015 -25.0% -8.85% 140K
|
Health Technology
|
| O: -0.34%
H: 0.0%
C: -5.13%
treatment lung cancer cancer antibody license
Sorrento Announces Positive Results From Its License Partner, Kelun, on a Phase I Study of Safety and Pharmacokinetics of A166, a Novel HER2 ADC for Advanced HER2 Positive Breast Cancers
Published: 2021-06-04 (Crawled : 20:00) - globenewswire.com
SRNE | $0.015 -25.0% -8.85% 140K
|
Health Technology
| Email alert
Add to watchlist
positive results positive results cancer license breast cancer her2+ her2- her2
Sorrento and Researchers at Karolinska Institutet Have Signed a Research Collaboration Agreement on iPSC-Derived Dimeric Antigen Receptor-Modified Natural Killer (DAR-NK) Cells With The Vision to Bring “Off-The-Shelf" NK Cell-Based Cancer Treatments Rapidly to Patients
Published: 2021-06-04 (Crawled : 18:00) - globenewswire.com
SRNE | $0.015 -25.0% -8.85% 140K
|
Health Technology
|
| O: 1.73%
H: 2.43%
C: -1.58%
treatment collaboration cancer research
Novel Anti-Cancer Drugs Permeate the Marketplace
Published: 2021-05-25 (Crawled : 13:15) - prnewswire.com
VSTM | $9.74 -1.02% -1.5% 95K
|
Health Technology
|
| O: 0.0%
H: 1.76%
C: -2.76%
SRNE | $0.015 -25.0% -8.85% 140K
|
Health Technology
|
| O: 0.7%
H: 3.18%
C: -2.35%
IMGN | News | $31.23 0.03% 49M
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: -4.69%
cancer drug
Lee’s Pharmaceutical Announces its Anti-PD-L1 Antibody Socazolimab, Licensed From Sorrento Therapeutics, Receives Clearance to Start Phase 3 Trial as a First-line Treatment of Extensive-stage Small-Cell Lung Cancer
Published: 2021-03-08 (Crawled : 04:00) - globenewswire.com
SRNE | $0.015 -25.0% -8.85% 140K
|
Health Technology
|
| O: 3.38%
H: 0.76%
C: -4.25%
treatment lung cancer cancer antibody license phase 3 trial clearance
Lee’s Pharmaceutical Announces Its Anti-PD-L1 Antibody Socazolimab, Licensed From Sorrento Therapeutics, Receives Breakthrough Therapy Designation in China for the Treatment of Recurrent or Metastatic Cervical Cancer
Published: 2021-02-09 (Crawled : 14:04) - globenewswire.com
SRNE | $0.015 -25.0% -8.85% 140K
|
Health Technology
|
| O: 0.73%
H: 3.43%
C: -3.07%
china therapy cancer treatment antibody license breakthrough therapy designation
Gainers vs Losers
| 72% | 28% |
Top 10 Gainers
AGBA | $2.5 100.0% 58.33% 200M
|
Finance
EDBL | News | $6.26 66.49% 48.56% 270K
|
MLEC | $2.47 76.43% 38.05% 460K
|
n/a
PEGY | $0.0458 -10.2% 28.77% 79M
|
Manufacturing
PROK | $2.72 33.33% 26.88% 20K
|
PALI | $4.93 4.67% 25.83% 2.1M
|
Manufacturing
SGD | $0.685 -1.71% 22.48% 2M
|
n/a
SILO | $1.99 0.71% 20.64% 1.8M
|
Finance and Insurance
NNVC | $1.12 1.82% 19.64% 2.5K
|
Health Technology
RIOT | $11.24 23.11% 17.75% 1.4M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.